Related Experiment Video
Updated: Jun 6, 2025
Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
Published on: January 9, 2019
Integrative Analysis Identifies NSUN2 as an Essential Coordinator for Glioma Malignancy and Glucose Metabolism
Yuze He1, Yunbo Yuan1, Linzi Ji2
1Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, China.
Background:
Glioma, particularly glioblastoma, is the most common and aggressive primary brain tumor, with poor prognosis due to its metabolic heterogeneity. NSUN2, an m5C RNA methyltransferase and direct glucose sensor, has been implicated in various malignancies, but its role in glioma remains unclear.
Methods:
Bioinformatic analysis was performed on multiple public databases and our glioma dataset from West China Hospital (WCH). In vitro experiments were conducted to assess the effects of NSUN2 knockdown on glioma cell proliferation, migration, and chemotherapeutic sensitivity. Transcriptomic analysis was employed to obtain mechanistic insights.
Results:
NSUN2 expression was significantly upregulated in gliomas and correlated with higher tumor grade and poor prognosis. NSUN2 knockdown reduced glioma cell proliferation, migration, and increased sensitivity to temozolomide. Transcriptomic analysis revealed that NSUN2 knockdown downregulated key genes involved in glioma progression. Mechanistically, NSUN2 positively regulates the activity of mTORC1 signaling, as indicated by phosphorylated S6 ribosomal protein and 4EBP1. Moreover, NSUN2 overexpression reciprocally increased tumor volume compared with controls, indicating NSUN2 promoting glioma cell proliferation in vivo.
Conclusions:
Our findings highlight NSUN2 as a critical regulator of glioma malignancy. Targeting NSUN2 disrupts key pathways in glioma progression, suggesting it as a promising therapeutic target. Our work underscores the potential of NSUN2 inhibition to enhance treatment efficacy and improve patient outcomes in glioma.
Insights
NSUN2, an RNA methyltransferase, is upregulated in glioma and drives tumor growth. Inhibiting NSUN2 reduces glioma progression and enhances chemosensitivity, offering a potential therapeutic strategy for brain tumors.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Glioma, especially glioblastoma, is an aggressive brain tumor with poor outcomes.
- Metabolic heterogeneity contributes to glioma's poor prognosis.
- The role of NSUN2 (NOP2 Sun RNA methyltransferase family member 2), an m5C RNA methyltransferase and glucose sensor, in glioma is not well understood.
Purpose of the Study:
- To investigate the role and clinical significance of NSUN2 in glioma.
- To explore the potential of targeting NSUN2 as a therapeutic strategy for glioma.
Main Methods:
- Bioinformatic analysis of public and hospital glioma datasets.
- In vitro experiments assessing NSUN2 knockdown effects on glioma cells (proliferation, migration, chemosensitivity).
- Transcriptomic analysis to elucidate molecular mechanisms.
- In vivo studies evaluating NSUN2 overexpression impact on tumor growth.
Main Results:
- NSUN2 expression is elevated in gliomas, correlating with higher tumor grade and poorer prognosis.
- NSUN2 knockdown inhibits glioma cell proliferation and migration, and increases sensitivity to temozolomide.
- NSUN2 positively regulates mTORC1 signaling and promotes glioma cell proliferation in vivo.
Conclusions:
- NSUN2 is a critical regulator of glioma malignancy.
- Targeting NSUN2 disrupts key glioma progression pathways.
- NSUN2 inhibition shows promise for enhancing glioma treatment efficacy and patient outcomes.
More Related Videos
09:40Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
Published on: October 4, 2019
05:45Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections
Published on: July 31, 2017